Cargando…

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma

BACKGROUND: Accumulating studies suggest that targeting epigenetic modifications could improve the efficacy of tumor immunotherapy; however, the mechanisms underlying this phenomenon remain largely unknown. Here, we investigated the ability of the epigenetic modifier, enhancer of zeste 2 polycomb re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Gang, Jin, Li-Lian, Liu, Chao-Qun, Wang, Yong-Chun, Meng, Ya-Ming, Zhou, Zhong-Guo, Chen, Jing, Yu, Xing-Juan, Zhang, Yao-Jun, Xu, Jing, Zheng, Limin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854886/ https://www.ncbi.nlm.nih.gov/pubmed/31727135 http://dx.doi.org/10.1186/s40425-019-0784-9

Ejemplares similares

Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma
por: Liu, Chao-Qun, et al.
Publicado: (2018)

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
por: Kuang, Dong-Ming, et al.
Publicado: (2009)

EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma
por: Guo, Baoping, et al.
Publicado: (2020)

Distinct patterns and prognostic values of tumor-infiltrating macrophages in hepatocellular carcinoma and gastric cancer
por: Li, Jin-Qing, et al.
Publicado: (2017)

Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
por: Wang, Yu-meng, et al.
Publicado: (2022)

IL-8-induced CXCR2 down-regulation in circulating monocytes in hepatocellular carcinoma is partially dependent on MAGL
por: Liu, Chong Zhong, et al.
Publicado: (2023)

GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma
por: Sun, Hong-Wei, et al.
Publicado: (2016)

Elevation of spermine remodels immunosuppressive microenvironment through driving the modification of PD-L1 in hepatocellular carcinoma
por: Shi, Hong-Xiang, et al.
Publicado: (2022)

Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma
por: He, Gaixia, et al.
Publicado: (2015)

Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma
por: Xie, Cheng-Rong, et al.
Publicado: (2015)

Distinct binding pattern of EZH2 and JARID2 on RNAs and DNAs in hepatocellular carcinoma development
por: Wen, Zhili, et al.
Publicado: (2022)

Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma
por: Liu, Li-Li, et al.
Publicado: (2020)

PD-L1 negatively regulates antifungal immunity by inhibiting neutrophil release from bone marrow
por: Yu, Yao, et al.
Publicado: (2022)

CLEC1B Expression and PD-L1 Expression Predict Clinical Outcome in Hepatocellular Carcinoma with Tumor Hemorrhage()()
por: Hu, Kuan, et al.
Publicado: (2018)

The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma
por: Wu, Shi-yi, et al.
Publicado: (2022)

Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
por: Ju, Feng, et al.
Publicado: (2023)

Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer
por: Tashireva, Liubov A., et al.
Publicado: (2023)

Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma
por: Chun, Hyung-Wook, et al.
Publicado: (2019)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD‐1/PD‐L1 negative schwannoma mimicking obstructive bronchial malignancy: A case report
por: Zhou, Daibing, et al.
Publicado: (2020)

Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
por: Jung, Hae Il, et al.
Publicado: (2017)

D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
por: Zhang, Ruonan, et al.
Publicado: (2022)

Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling
por: Yu, Chao, et al.
Publicado: (2023)

Analysis on EZH2: mechanism identification of related CeRNA and its immunoassay in hepatocellular carcinoma
por: Zhao, Haoran, et al.
Publicado: (2023)

Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma
por: Zeng, Zhen, et al.
Publicado: (2011)

The relationship between the expression of USP22, BMI1, and EZH2 in hepatocellular carcinoma and their impacts on prognosis
por: Zhai, Run, et al.
Publicado: (2016)

Effects of EZH2 Polymorphisms on Susceptibility to and Pathological Development of Hepatocellular Carcinoma
por: Yu, Yung-Luen, et al.
Publicado: (2013)

EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
por: Wang, Bohan, et al.
Publicado: (2023)

Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer
por: Chen, Jing, et al.
Publicado: (2021)

Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma
por: Ma, Li-Jie, et al.
Publicado: (2018)

Inhibition of EZH2 Ameliorates Sepsis Acute Lung Injury (SALI) and Non-Small-Cell Lung Cancer (NSCLC) Proliferation through the PD-L1 Pathway
por: Wang, Ziyi, et al.
Publicado: (2022)

The predictive value of PD‐L1 expression in patients with advanced hepatocellular carcinoma treated with PD‐1/PD‐L1 inhibitors: A systematic review and meta‐analysis
por: Yang, Yao, et al.
Publicado: (2023)

Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma
por: Wang, Jiting, et al.
Publicado: (2021)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis
por: Böttcher, Martin, et al.
Publicado: (2021)

CTHRC1 and PD-1/PD-L1 expression predicts tumor recurrence in prostate cancer
por: Zhou, Qing, et al.
Publicado: (2019)

Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma
por: Gong, Xue-Qin, et al.
Publicado: (2023)

Analysis of EZH2 Genetic Variants on Triple-Negative Breast Cancer Susceptibility and Pathology
por: Liu, Liang-Chih, et al.
Publicado: (2022)

The role of EZH1 and EZH2 in development and cancer
por: Lee, Soo Hyun, et al.
Publicado: (2022)

5-Methoxyquinoline Derivatives as a New Class of EZH2 Inhibitors
por: Xiang, Pu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v0gtkjr6erc1bia00agg1tmk2n